Didier Véron
Direttore/Membro del Consiglio presso Leem
Profilo
Didier Véron is a Member-Supervisory Board at Leem.
He was a Director-Corporate Communications at Tercica, Inc. from 2012 to 2014.
He was also a SVP-Public Affairs & Corporate Communications at Ipsen SA from 2013 to 2018.
Mr. Véron has an undergraduate degree from Sciences Po and a graduate degree from Université de Paris XI Paris Sud.
Posizioni attive di Didier Véron
| Società | Posizione | Inizio |
|---|---|---|
| Leem | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Didier Véron
| Società | Posizione | Fine |
|---|---|---|
| IPSEN | Public Communications Contact | 01/12/2018 |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Public Communications Contact | 03/02/2014 |
Formazione di Didier Véron
| Sciences Po | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| IPSEN | Health Technology |
| Aziende private | 3 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
| Leem | |
| Université de Paris XI Paris Sud | Consumer Services |
- Borsa valori
- Insiders
- Didier Véron
